Emily Bodnar
Stock Analyst at H.C. Wainwright
(4.25)
# 1,456
Out of 4,983 analysts
685
Total ratings
40.7%
Success rate
7.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ODTX Odyssey Therapeutics | Reiterated: Buy | $44 | $23.22 | +89.49% | 2 | Sep 9, 2026 | |
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $57 | $39.20 | +45.41% | 6 | Sep 3, 2026 | |
| TGTX TG Therapeutics | Reiterated: Buy | $78 | $56.47 | +38.13% | 14 | Sep 1, 2026 | |
| JSPR Jasper Therapeutics | Reiterated: Buy | $20 | $0.6341 | +3,054.08% | 22 | Aug 18, 2026 | |
| GNLX Genelux | Reiterated: Buy | $31 | $2.53 | +1,125.30% | 16 | Aug 14, 2026 | |
| IMNN Imunon | Reiterated: Buy | $25 | $1.38 | +1,711.59% | 27 | Aug 14, 2026 | |
| INKT MiNK Therapeutics | Reiterated: Buy | $35 | $11.71 | +198.89% | 27 | Aug 14, 2026 | |
| ACRV Acrivon Therapeutics | Reiterated: Buy | $19 | $1.70 | +1,017.65% | 25 | Aug 13, 2026 | |
| NXTC NextCure | Reiterated: Buy | $20 | $5.67 | +252.73% | 16 | Aug 13, 2026 | |
| AGEN Agenus | Rated: Buy | $30 → $25 | $7.22 | +246.26% | 41 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.92 | +420.83% | 8 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $52 → $60 | $41.19 | +45.67% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $14 | $2.81 | +398.22% | 31 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $36 | $9.90 | +263.64% | 47 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.10 | +125.81% | 27 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $17 | $1.55 | +1,000.32% | 20 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $8.44 | +314.69% | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $42 | $31.40 | +33.76% | 11 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.3834 | +1,204.12% | 39 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $25.54 | +76.19% | 21 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.50 | +185.71% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.32 | - | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $55 | $33.61 | +63.64% | 24 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $52 | $16.72 | +211.00% | 45 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.40 | - | 27 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $0.313 | +3,733.87% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 → $66 | $55.06 | +19.87% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $5.11 | +252.25% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0002 | - | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55.48 | $5.92 | +837.14% | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $2.55 | +6,174.51% | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.72 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.29 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.71 | n/a | 6 | May 22, 2024 |
Odyssey Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $44
Current: $23.22
Upside: +89.49%
First Tracks Biotherapeutics
Sep 3, 2026
Reiterated: Buy
Price Target: $57
Current: $39.20
Upside: +45.41%
TG Therapeutics
Sep 1, 2026
Reiterated: Buy
Price Target: $78
Current: $56.47
Upside: +38.13%
Jasper Therapeutics
Aug 18, 2026
Reiterated: Buy
Price Target: $20
Current: $0.6341
Upside: +3,054.08%
Genelux
Aug 14, 2026
Reiterated: Buy
Price Target: $31
Current: $2.53
Upside: +1,125.30%
Imunon
Aug 14, 2026
Reiterated: Buy
Price Target: $25
Current: $1.38
Upside: +1,711.59%
MiNK Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $35
Current: $11.71
Upside: +198.89%
Acrivon Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $19
Current: $1.70
Upside: +1,017.65%
NextCure
Aug 13, 2026
Reiterated: Buy
Price Target: $20
Current: $5.67
Upside: +252.73%
Agenus
Aug 11, 2026
Rated: Buy
Price Target: $30 → $25
Current: $7.22
Upside: +246.26%
Aug 11, 2026
Reiterated: Buy
Price Target: $10
Current: $1.92
Upside: +420.83%
Aug 11, 2026
Rated: Buy
Price Target: $52 → $60
Current: $41.19
Upside: +45.67%
Aug 11, 2026
Rated: Buy
Price Target: $16 → $14
Current: $2.81
Upside: +398.22%
Aug 11, 2026
Reiterated: Buy
Price Target: $38 → $36
Current: $9.90
Upside: +263.64%
Aug 11, 2026
Reiterated: Buy
Price Target: $7
Current: $3.10
Upside: +125.81%
Aug 10, 2026
Rated: Buy
Price Target: $30 → $17
Current: $1.55
Upside: +1,000.32%
Aug 7, 2026
Reiterated: Buy
Price Target: $35
Current: $8.44
Upside: +314.69%
Aug 7, 2026
Rated: Buy
Price Target: $45 → $42
Current: $31.40
Upside: +33.76%
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $0.3834
Upside: +1,204.12%
Aug 6, 2026
Reiterated: Buy
Price Target: $45
Current: $25.54
Upside: +76.19%
Aug 6, 2026
Reiterated: Buy
Price Target: $10
Current: $3.50
Upside: +185.71%
Aug 5, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.32
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: $52 → $55
Current: $33.61
Upside: +63.64%
Jul 24, 2026
Rated: Buy
Price Target: $46 → $52
Current: $16.72
Upside: +211.00%
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $2.40
Upside: -
May 15, 2026
Reiterated: Buy
Price Target: $12
Current: $0.313
Upside: +3,733.87%
Mar 30, 2026
Reiterated: Buy
Price Target: $55 → $66
Current: $55.06
Upside: +19.87%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $5.11
Upside: +252.25%
Nov 17, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.0002
Upside: -
Oct 13, 2025
Reiterated: Buy
Price Target: $55.48
Current: $5.92
Upside: +837.14%
Sep 26, 2025
Reiterated: Buy
Price Target: $160
Current: $2.55
Upside: +6,174.51%
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $1.72
Upside: n/a
Mar 31, 2025
Reiterated: Buy
Price Target: $8
Current: $1.29
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $1.71
Upside: n/a